Three of the five individual TAAs, FKBP52, PPIA, and PRDX2, showed significantly increased reactivity in breast carcinoma patients and breast carcinoma in situ patients compared to healthy controls. This evidence concerns the gene FKBP4 and lobular breast carcinoma in situ.